Dosimetric benefits of adaptive radiation therapy for patients with stage III non-small cell lung cancer

Dosimetric benefits of adaptive radiation therapy for patients with stage III non-small cell lung cancer

Abstract Background Daily adaptive radiation therapy (ART) of patients with non-small cell lung cancer (NSCLC) lowers organs at risk exposure while maintaining the planning target volume (PTV) coverage. Thus, ART allows an isotoxic approach with increased doses to the PTV that could improve local tu...

Full description

Bibliographic Details
Main Authors: Lea Hoppen, Gustavo R. Sarria, Chung S. Kwok, Judit Boda-Heggemann, Daniel Buergy, Michael Ehmann, Frank A. Giordano, Jens Fleckenstein
Format: Article
Language:English
Published: BMC 2023-02-01
Series:Radiation Oncology
Subjects:
Adaptive radiation therapy
stage III NSCLC
Isotoxic dose-escalation
Isoeffective organ at risk sparing
Online Access:https://doi.org/10.1186/s13014-023-02222-7

Internet

https://doi.org/10.1186/s13014-023-02222-7

Similar Items